Evaluation of the Efficacy of Two Dietary Supplements on Hair Loss and Hair Aspect

NCT ID: NCT06028295

Last Updated: 2024-04-01

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

99 participants

Study Classification

INTERVENTIONAL

Study Start Date

2023-09-04

Study Completion Date

2023-12-21

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The study is aimed to assess the efficacy of two dietary supplements composed of a Wheat Polar Lipid Complex (WPLC) in oil or powder form in reducing hair loss and improving hair aspect.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

A double blind, parallel groups, placebo-controlled study is carried out on 90 healthy female subjects aged between 18 and 65 years old with all hair type showing diffuse and temporary hair shedding with a proportion of hair in telogen phase \>15%. The study foresees 84 days of products intake. Evaluations of the parameters under study are performed at baseline, after 56 and 84 days of products consumption.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Healthy Volunteers

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Wheat Polar Lipid Complex Oil

Dietary supplement - Wheat Polar Lipid Complex (Oil)

Group Type EXPERIMENTAL

Wheat Polar Lipid Complex Oil

Intervention Type DIETARY_SUPPLEMENT

The study foresees the intake of 2 capsules per day during 84 days

Wheat Polar Lipid Complex Powder

Dietary supplement - Wheat Polar Lipid Complex (Powder)

Group Type EXPERIMENTAL

Wheat Polar Lipid Complex Powder

Intervention Type DIETARY_SUPPLEMENT

The study foresees the intake of 2 capsules per day during 84 days

Placebo

Dietary supplement - Placebo

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DIETARY_SUPPLEMENT

The study foresees the intake of 2 capsules per day during 84 days

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Wheat Polar Lipid Complex Oil

The study foresees the intake of 2 capsules per day during 84 days

Intervention Type DIETARY_SUPPLEMENT

Wheat Polar Lipid Complex Powder

The study foresees the intake of 2 capsules per day during 84 days

Intervention Type DIETARY_SUPPLEMENT

Placebo

The study foresees the intake of 2 capsules per day during 84 days

Intervention Type DIETARY_SUPPLEMENT

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Healthy female subjects,
* Caucasian ethnicity,
* Age between 18 and 65 years old (extremes included),
* All hair type included,
* Subject showing acute hair shedding (duration less than 6 months) due to fatigue, seasonal change, deficiency of vitamins and minerals, stress, change or imbalance of normal daily routing, or emotional stress,
* Women showing a proportion of hair in telogen phase \> 15%,
* Subjects complaining brittle and thin hair,
* Subjects who stopped any anti hair loss treatment at least 3 months prior the study,
* Subjects agreeing not to take any treatment (oral or topic) able to interfere with the hair growth, diameter or fall during the whole study duration,
* Subjects who have not been involved in any other similar study in the last 3 months,
* Subjects registered with health social security or health social insurance, Subjects able to understand the language used in the investigation center and the information given
* Subjects able to comply with the protocol and follow protocol's constraints and specific requirements
* Willingness to use the same products for hair care during all the study period
* Willingness not to cut hair for all the study length.
* Subjects having signed their written Informed Consent form (ICF) for their participation in the study and a photograph authorization.

* Subject is taking part or planning to participate to another clinical study in the same or in another investigation centre,
* Subject is deprived of freedom by administrative or legal decision or under guardianship,
* Subject is admitted in a sanitary or social facilities,
* Subject is planning an hospitalization during the study,
* Subject has participated in another clinical study with anti-hair loss product or treatment within the last 3 months before the inclusion visit,
* Subject is breastfeeding, pregnant or not willing to take necessary precautions to avoid pregnancy during the study (for the women of childbearing potential),
* Subject has started or changed oestrogen-progesterone contraception or hormonal treatment, within the 3 months prior to the study or foreseeing it for the duration of the study,
* Subject having an acute, chronic or progressive illness liable to interfere with the study data or considered by the Investigator hazardous for the subject or incompatible with the study requirements,
* Subject is in course of a long-treatment or intending to have one considered by the Investigator liable to interfere with the study data or incompatible with the study requirements,
* Subject having a skin/scalp condition liable to interfere with the study data or considered by the Investigator hazardous for the subject or incompatible with the study requirements,
* Subject having personal history of cosmetic, drug, domestic products or food supplements allergy,
* Subject having food disorders,
* Subject who has any other hair disorder or hair disease (female pattern hair loss, any type of alopecia...),
* Subject having excessive and/or fluctuating hair shedding for more than 6 months,
* History or clinical signs of hyperandrogenemia (menstrual cycle \>35 days and hirsutism and acne),
* Systemic treatment affecting the hair growth taken for more than 4 consecutive weeks during the last 24 weeks before inclusion visit: retinoids, anti-mitotic, cytotoxic drugs other than antineoplastic, anti-androgens (spironolactone, flutamide), androgens, anti-epileptic agents, interferon alpha,
* Systemic or local androgenetic alopecia treatment or product, taken or applied (Minoxidil, Aminexil, Finasteride, Dutasteride, cosmetic solution or capsules with vitamin B, zinc, caffeine...) for more than 4 consecutive weeks during the last 24 weeks before the inclusion visit,
* Any other topical treatment applied on the scalp (non-steroidal anti-inflammatory, ketoconazole...) within the last 2 weeks before the inclusion visit,
* No hair wash in the 48 hours before each visit,
* Any following hair care within the last 2 weeks before each visit: dandruff shampoo, antifungal shampoo, dyeing, bleaching, perm,
* Any hair care product applied on the scalp between the last shampoo and the inclusion visit (e.g. gel, hairspray, wax, foam...),
* Radiotherapy, chemotherapy at any time,
* Scalp surgery (hair transplants, laser) at any time.
Minimum Eligible Age

18 Years

Maximum Eligible Age

65 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Seppic

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Ileana De Ponti

Role: STUDY_DIRECTOR

Complife Italia S.r.l

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Complife Italia srl

Milan, , Italy

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Italy

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

IT0003622/23

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.